文献速递炎症性肠病

挥发性有机化合物在检测溃疡性结肠炎活动性疾病中的潜力

The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-26

本研究纳入72例溃疡性结肠炎(UC)患者(132份呼气样本,其中活动期62份、缓解期70份)和22例非UC结肠炎患者,采用气相色谱-飞行时间质谱分析呼气挥发性有机化合物(VOCs)。11种VOCs在独立内部验证集中预测活动期与缓解期UC的灵敏度为92%、特异度为77%(AUC 0.94),主成分分析可清晰区分非UC结肠炎与UC患者。

要点

  • 11种VOCs在独立内部验证集中预测活动期与缓解期UC,灵敏度92%、特异度77%(AUC 0.94)。
  • 主成分分析可清晰区分非UC结肠炎患者与活动期及缓解期UC患者。
  • VOCs展现出作为监测UC炎症的新型非侵入性生物标志物的潜力。

核心结论

  • 挥发性有机化合物能准确区分UC活动期与缓解期,且UC的VOCs谱与非UC结肠炎患者明显不同。
  • VOCs展现出作为监测UC炎症的新型非侵入性生物标志物的潜力。

研究设计与样本

  • UC患者参与为期1年的研究,每次门诊随访收集临床活动指数、血液、粪便和呼气样本。
  • 横断面分析纳入粪钙卫蛋白>250 μg/g的明确活动期患者,以及简单临床结肠炎活动指数<3、C反应蛋白<5 mg/L且粪钙卫蛋白<100 μg/g的非活动期患者。
  • 非UC结肠炎通过粪便培养或影像学评估确认。
  • 呼气样本采用气相色谱-飞行时间质谱和基于核的方法分析以识别有鉴别力的VOCs。
  • 共纳入72例UC患者(132份呼气样本,活动期62份、缓解期70份)和22例非UC结肠炎患者(22份样本)。

主要发现

  • 11种VOCs在独立内部验证集中预测活动期与缓解期UC,灵敏度92%、特异度77%(AUC 0.94)。
  • 主成分分析可清晰区分非UC结肠炎患者与活动期及缓解期UC患者。

关键数值与推荐

  • 活动期定义:粪钙卫蛋白>250 μg/g。
  • 非活动期定义:简单临床结肠炎活动指数<3、C反应蛋白<5 mg/L且粪钙卫蛋白<100 μg/g。
  • 11种VOCs预测活动期与缓解期UC:灵敏度92%、特异度77%、AUC 0.94(独立内部验证集)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To optimise treatment of ulcerative colitis (UC), patients need repeated assessment of mucosal inflammation. Current non-invasive biomarkers and clinical activity indices do not accurately reflect disease activity in all patients and cannot discriminate UC from non-UC colitis. Volatile organic compounds (VOCs) in exhaled air could be predictive of active disease or remission in Crohn's disease. AIM: To investigate whether VOCs are able to differentiate between active UC, UC in remission and non-UC colitis. METHODS: UC patients participated in a 1-year study. Clinical activity index, blood, faecal and breath samples were collected at each out-patient visit. Patients with clear defined active faecal calprotectin >250 μg/g and inactive disease (Simple Clinical Colitis Activity Index <3, C-reactive protein <5 mg/L and faecal calprotectin <100 μg/g) were included for cross-sectional analysis. Non-UC colitis was confirmed by stool culture or radiological evaluation. Breath samples were analysed by gas chromatography time-of-flight mass spectrometry and kernel-based method to identify discriminating VOCs. RESULTS: In total, 72 UC (132 breath samples; 62 active; 70 remission) and 22 non-UC-colitis patients (22 samples) were included. Eleven VOCs predicted active vs. inactive UC in an independent internal validation set with 92% sensitivity and 77% specificity (AUC 0.94). Non-UC colitis patients could be clearly separated from active and inactive UC patients with principal component analysis. CONCLUSIONS: Volatile organic compounds can accurately distinguish active disease from remission in UC and profiles in UC are clearly different from profiles in non-UC colitis patients. VOCs have demonstrated potential as new non-invasive biomarker to monitor inflammation in UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Smolinska A, Bodelier AG, Dallinga JW, et al. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 28239876. doi:10.1111/apt.14004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。